在喘,COPD,ACO和一般人群中处方宏类药物和预防性心电图:药物利用研究
Victor Pera1, Heleen Lepouttre1,2, Cesar Barboza1
1Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
概括
长期使用宏类药物治疗慢性呼吸道疾病 (如慢性肺炎和喘) 的情况正在增加,但治疗前对心电图 (ECG) 的监测仍然很少见,尽管由于潜在的心脏风险,指南建议使用它.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 对于慢性呼吸道疾病,Macrolides是用来预防恶化症的.
- 长期使用宏类药物需要对心电图 (ECG) 进行评估,因为可能会延长QT间隔.
研究的目的:
- 为了确定使用宏类药物 (阿齐思罗米,克拉里思罗米,红素) 在喘,COPD和喘-COPD重叠 (ACO) 的发生率.
- 评估在开始长期宏类药物治疗之前进行心电图的频率.
主要方法:
- 利用了来自荷兰IPCI和西班牙SIDIAP数据库 (2006-2022) 的数据.
- 分析了按宏类型,数据库,年份和使用时间 (短期,中长期,长期) 的发病率.
- 包括患有喘,COPD和ACO的人,至少进行365天的随访.
主要成果:
- 每10万人/年发生的短期类药物发生率各不相同:阿齐思罗米 (3500-6700),克拉里思罗米 (1300-2100),红 (200-300).
- 中长期使用的发病率为<1100/100,000人/年,COPD和ACO的发病率高于喘.
- 不到1%的长期使用类药物的患者在治疗前记录了心电图.
结论:
- 长期的宏类药物处方在COPD和ACO人群中正在增加.
- 电心电图 (ECG) 监测很少在长期使用类药物之前进行,违反指导方针.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
01:26COPD: Management Using Bronchodilators and Corticosteroids
706
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
706
01:24Antiasthma Drugs: Methylxanthines
1.6K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K